Peter Pinto

Principal Investigator, Chief Prostate Cancer Section

National Cancer Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Purpose: Clinical risk grouping based on PSA, tumor grade, and disease extent guides treatment intensity for localized prostate cancer. However, many patients with intermediate- or high-risk disease treated with external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) still develop biochemical recurrence (BCR). Early identification of patients at high risk for BCR could enable personalized treatment strategies. Experimental Design: We prospectively enrolled 29 patients with intermediate- or high-risk prostate cancer undergoing EBRT and ADT. Pretreatment biopsies ( n = 60) underwent whole-transcriptome microarray and whole-exome sequencing. Patients received multiparametric MRI at baseline and 6 months after treatment, with a median follow-up of 6 years. Gene expression differences between patients with and without BCR were analyzed using pathway tools and validated in external datasets. A novel TGF-β gene signature was derived and tested across multiple cohorts (median follow-up: 5–11 years). Results: TGF-β activity was significantly associated with BCR in the discovery cohort ( P = 0.0081) and correlated with PTEN/TP53 alterations ( P = 0.0246) and baseline multiparametric MRI tumor volume ( P = 0.026). TGF-β activity also predicted metastasis-free survival ( P = 0.037) and, in an independent cohort ( n = 265), was prognostic for BCR-free ( P = 0.05), metastasis-free ( P P Conclusions: TGF-β activity is a dominant feature of intermediate- to unfavorable-risk prostate tumors prone to biochemical failure after EBRT with ADT and may serve as an independent prognostic biomarker beyond existing clinical criteria.

Year:

2025

Purpose Poor quality prostate MRI images, especially ADC maps, can lead to missed lesions and unnecessary repeat scans. To address this issue, we aimed to develop an automated method to predict ADC map quality from T2 images acquired earlier in the scanning process. Materials and Methods A paired multi-site image corpus of T2-weighted images and ADC maps was constructed from 486 patients imaged in-house and at 62 external clinics. A senior radiologist assigned 1-3 quality ratings to each image set, later converted to a binary “non-diagnostic” or “diagnostic” scale. A deep learning model and a rectal cross-sectional area measurement approach were developed to predict ADC image quality from T2 images. Model performance was evaluated retrospectively by accuracy, sensitivity, negative and positive predictive value, and AUC. Results No single acquisition parameter in the metadata was statistically associated with image quality for either T2 or ADC maps. Quality scores of the same modality showed low correlation across sites (r∼0.2). In the challenging task of predicting ADC quality from prior T2 images, our model achieved performance comparable to current single-site models directly using ADC maps, with 83% sensitivity and 90% negative predictive value. The model showed stronger performance on in-house data (94±2% accuracy) despite being trained exclusively on multicenter external data. Rectal cross-sectional area on T2 images provided an interpretable quality metric (AUC 0.65). Conclusion The probability of low quality, uninterpretable ADC maps can be inferred early in the imaging process by neural network approach, allowing corrective action to be employed.

Year:

2025

Patients diagnosed with localized high-risk prostate cancer have higher rates of recurrence, and the introduction of neoadjuvant intensive hormonal therapies seeks to treat occult micrometastatic disease by their addition to definitive treatment. Sufficient profiling of baseline disease has remained a challenge in enabling the in-depth assessment of phenotypes associated with exceptional vs. poor pathologic responses after treatment. In this study, we report comprehensive and integrative gene expression profiling of 37 locally advanced prostate tumors prior to six months of androgen deprivation therapy (ADT) plus the androgen receptor (AR) inhibitor enzalutamide prior to radical prostatectomy. A robust transcriptional program associated with HER2 activity was positively associated with poor outcome and opposed AR activity, even after adjusting for common genomic alterations in prostate cancer including PTEN loss and expression of the TMPRSS2:ERG fusion. Patients experiencing exceptional pathologic responses demonstrated lower levels of HER2 and phospho-HER2 by immunohistochemistry of biopsy tissues. The inverse correlation of AR and HER2 activity was found to be a universal feature of all aggressive prostate tumors, validated by transcriptional profiling an external cohort of 121 patients and immunostaining of tumors from 84 additional patients. Importantly, the AR activity-low, HER2 activity-high cells that resist ADT are a pre-existing subset of cells that can be targeted by HER2 inhibition alone or in combination with enzalutamide. In summary, we show that prostate tumors adopt an AR activity-low prior to antiandrogen exposure that can be exploited by treatment with HER2 inhibitors. ClinicalTrials.gov registration: NCT02430480 .

Year:

2024

Collaborators (7)

William A. Hall

-

UNITED STATES
View details

Bradford Wood

Adjunct Professor

University of Maryland

UNITED STATES
View details

Deborah Citrin

National Cancer Institute

UNITED STATES
View details

Adam Sowalsky

Senior Investigator

National Cancer Institute

UNITED STATES
View details

Peter Choyke

Senior Investigator

National Cancer Institute

UNITED STATES
View details

Melvin Chua

Professor (with Tenure)

Duke-NUS Medical School

SINGAPORE
View details

Radka Stoyanova

Professor and Director of Imaging and Biomarkers

University of Miami

UNITED STATES
View details